Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04384393 | Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies | unknown | Phase 1 | 30 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05158608 | Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis(CY25) | unknown | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 0 | Jan 11, 2022 |
| clinicaltrials |
| NCT05184595 | Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib(ADHOMY2) | unknown | N/A | 52 | Central Hospital, Nancy, FranceOTHER | 0 | Jan 11, 2022 | clinicaltrials |
| NCT01752062 | Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors(CML1012) | unknown | — | 148 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01761890 | Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib(CML1113) | unknown | — | 147 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05179213 | Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT03751917 | Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia(APL0618) | unknown | — | 100 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT04640909 | Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients | unknown | N/A | 23 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05133310 | Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia | unknown | Phase 4 | 108 | Hospital General de MexicoOTHER_GOV | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05176275 | PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells | unknown | N/A | 10 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Jan 4, 2022 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05152537 | FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor(TKI)Stopping in Chronic Myeloid Leukemia(NTU-CML-001) | unknown | — | 15 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | unknown | Phase 2 / Phase 3 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05023707 | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT03821519 | Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant(Haplo-CIK) | unknown | Phase 1 / Phase 2 | 20 | A.O. Ospedale Papa Giovanni XXIIIOTHER | 1 | Dec 23, 2021 | clinicaltrials |
| NCT05167630 | Prognosis Factors in Patients With Primary Central Nervous System Lymphoma | unknown | — | 40 | Zhengzhou UniversityOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT05164770 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 160 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05145101 | Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia(Pneumo-CLL) | unknown | — | 150 | Hannah Garcia GarridoOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT05164042 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT05137886 | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | unknown | Phase 2 | 47 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05156554 | PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation | unknown | N/A | 80 | Sun Yat-sen UniversityOTHER | 0 | Dec 14, 2021 | clinicaltrials |
| NCT05155215 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 68 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05149170 | Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT04722952 | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML | unknown | Phase 3 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05143112 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05008536 | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 27 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05130424 | A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province | unknown | — | 498 | SuxiaLuoOTHER_GOV | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04789434 | PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT | unknown | Phase 3 | 94 | Ruijin HospitalOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT05097443 | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 130 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05127135 | Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies | unknown | Phase 1 | 30 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05127798 | RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old. | unknown | — | 50 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05123352 | Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies | unknown | — | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04752527 | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features | unknown | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04014894 | ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma | unknown | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04818372 | Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | unknown | Phase 1 | 87 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Nov 12, 2021 | clinicaltrials |
| NCT05076097 | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma | unknown | Phase 2 | 29 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05106946 | Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma | unknown | Phase 1 | 20 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05114109 | Isatuximab in Type I Cryoglobulinemia(ICE) | unknown | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT04674345 | Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia | unknown | Phase 2 / Phase 3 | 346 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT05017883 | TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia | unknown | N/A | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05106907 | Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma | unknown | Phase 1 | 20 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated(ALIVE) | unknown | Phase 3 | 315 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT05100303 | A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04613622 | Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia | unknown | — | 500 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT04616274 | Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia | unknown | — | 500 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT04846439 | Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Jan 11, 2022source: clinicaltrials